A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus.

Diabetes Ther · 2020 · PMC7434819 · PMID 32725484

Europe PMC DOI

hedged sentence

0.1700

closest p · 3.4× alpha

0.1700

boldest claim

The sentences

did not reach statistical significancep = 0.17not close (p > 0.1)

An HR of 0.79 in favour of orally administered semaglutide compared with placebo was observed, but this 21% reduction in MACE did not reach statistical significance ( p = 0.17 for superiority).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.